Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.75
Bid: 12.50
Ask: 13.00
Change: 0.125 (0.99%)
Spread: 0.50 (4.00%)
Open: 12.625
High: 12.75
Low: 12.50
Prev. Close: 12.75
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Scancell developing 'promising' new cancer treatment approach

Thu, 23rd Jun 2022 12:38

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

The AIM-traded firm said TCB antibodies have dual-binding specificity, which crosslinks tumour cells via their glycans with an activating receptor CD3 on T-cells.

That results in activation of killer T-cells, and tumour cell death.

Scancell said the antibodies were "particularly potent" in tumours which have lost the T-cell recognition molecule major histocompatibility antigen (MHC), or where there was limited T-cell infiltration as they bypassed normal T-cell activation pathways and redirect the host immune system to the tumour.

The company said it was currently in the preclinical research phase, and expected to take the novel product into a phase 1 clinical study.

It said it believed the project would provide a "strong validation and demonstration of value" for the whole GlyMab antibody platform.

To create TCB antibodies, Scancell said it would combine its proprietary GlyMab antibodies, which target sugar motifs rather than proteins and are designed to have superior affinity and selectivity profiles, with in-licenced Fc silencing technology from the Oxford-based mAbsolve.

The technology from mAbsolve would reduce the likelihood of toxicity caused by cytokine storms, which could be associated with clinical antibodies engaging the immune system.

Scancell said it would leverage its understanding of cancer immunotherapy and T-cell immunology together with its strong development capabilities to bring the TCB antibodies to clinical validation, adding value to the entire GlyMab platform.

At the same time, the firm said it would use the GlyMab platform to deliver cytotoxic drugs (ADC) or cell therapies (CAR).

The board said it intended to realise the potential of those approaches for the GlyMab antibodies through strategic partnerships with third parties.

"Over the past year we have been evaluating the optimal products for Scancell to develop through exploiting our GlyMab platform," said chief executive officer Lindy Durrant.

"We believe we can add considerable value to the antibody portfolio by taking TCB products into the clinic, as opposed to out-licensing them at the preclinical stage.

"At the same time, the Board continues to evaluate opportunities to enter into revenue generating deals for our antibodies with ADC or CAR companies."

At 1115 BST, shares in Scancell Holdings were down 3.73% at 14.2p.

Reporting by Josh White at Sharecast.com.

More News
23 Jun 22 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:...

Read more
15 Jun 22 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK....

Read more
15 Jun 22 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval....

Read more
13 Jun 22 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersm...

Read more
11 Apr 22 13:10

Scancell opens recruitment for cancer therapy trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that its phase 1 and 2 clinical trial with 'Modi-1' is open for recruitment....

Read more
11 Apr 22 12:02

LONDON MARKET MIDDAY: CAC moves green for Macron, FTSE 100 lags

(Alliance News) - Stocks in Europe were having a mixed day on Monday, with the FTSE 100 feeling the weight of a poor UK GDP reading, but the CAC 40 in Paris gaining as investors in France show confide...

Read more
11 Apr 22 11:17

Scancell shares soar as clinical trial opens for recruitment

(Alliance News) - Scancell Holdings PLC shares soared on Monday after the cancer immunotherapies developer said its phase 1/2 clinical trial with Modi-1 has opened for recruitment....

Read more
29 Mar 22 19:21

IN BRIEF: Scancell broadens Covidity clinical trial in South Africa

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Updates on South African Health Products Regulatory Authority's approval of a protocol amendment to the phase 1 Cov...

Read more
17 Mar 22 21:02

TRADING UPDATES: SimiGon merger to go ahead; Segro launches green bond

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:...

Read more
22 Feb 22 11:50

Image Scan sinks as it expects to post significant loss in first half

(Alliance News) - Image Scan Holdings PLC shares tanked on Tuesday after the company said it expects to post a significant loss for the first half of financial 2022 and thinks it is "unlikely" that th...

Read more
31 Jan 22 22:07

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views...

Read more
26 Jan 22 20:18

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit...

Read more
19 Jan 22 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days...

Read more
19 Nov 21 13:49

Scancell treats first patient in melanoma tumour trial

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell announced on Friday that the enrolment and treatment of the first patient had taken place in its multicentre phase 2 c...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.